Patient characteristics at baseline
| Characteristic | Lansoprazole 15 mg (n=217) | Vonoprazan 10 mg (n=202) | Vonoprazan 20 mg (n=202) |
| Age, mean (SD) years | 68.3 (9.06) | 68.9 (8.02) | 69.1 (7.18) |
| Gender, n (%) | |||
| Male | 178 (82.0) | 166 (82.2) | 163 (80.7) |
| Female | 39 (18.0) | 36 (17.8) | 39 (19.3) |
| BMI, mean (SD) kg/m2 | 24.48 (3.234) | 24.40 (3.395) | 23.68 (3.334) |
| Current or ex-smoker, n (%) | 168 (77.4) | 158 (78.2) | 161 (79.7) |
| Alcohol consumption, n (%) | 120 (55.3) | 128 (63.4) | 118 (58.4) |
| Underlying disease, n (%) | |||
| Ischaemic heart disease | 136 (62.7) | 121 (59.9) | 119 (58.9) |
| Ischaemic cerebrovascular disorder | 71 (32.7) | 76 (37.6) | 80 (39.6) |
| Other | 39 (18.0) | 44 (21.8) | 49 (24.3) |
| Helicobacter pylori status, n (%) | |||
| Negative | 127 (59.6) | 118 (58.4) | 119 (59.2) |
| Positive | 86 (40.4) | 84 (41.6) | 82 (40.8) |
| CYP2C19 polymorphism, n (%) | |||
| Extensive metaboliser | 187 (87.0) | 163 (81.5) | 160 (79.6) |
| Poor metaboliser | 28 (13.0) | 37 (18.5) | 41 (20.4) |
| Dosage of long-term LDA, n (%) | |||
| 100 mg/day (or 81 mg/day aspirin/dialuminate) | 209 (96.3) | 194 (96.0) | 193 (95.5) |
| 200 mg/day (or 162 mg/day aspirin/dialuminate) | 8 (3.7) | 8 (4.0) | 9 (4.5) |
| Other antithrombotic drug*, n (%) | 91 (41.9) | 85 (42.1) | 81 (40.1) |
*Clopidogrel, warfarin, ticlopidine or others (additional analysis).
BMI, body mass index; CYP, cytochrome P450; LDA, low-dose aspirin.